AMPL vs DBD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 08, 2026

AMPL

33.5
AI Score
VS
DBD Wins

DBD

48.5
AI Score

Investment Advisor Scores

AMPL

34score
Recommendation
AVOID NEW MONEY

DBD

49score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric AMPL DBD Winner
Forward P/E 69.4444 12.6422 DBD
PEG Ratio 0 0 Tie
Revenue Growth 21.2% 5.2% AMPL
Earnings Growth 0.0% -82.9% AMPL
Tradestie Score 33.5/100 48.5/100 DBD
Profit Margin -26.6% 2.0% DBD
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY BUY DBD

Relative Price Performance (Last 90 Days)

AMPL 1M: +10.2% · 3M: +29.4% DBD 1M: -12.5% · 3M: -21.0%

Current Technical Phase

AMPL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (11.6% over 20 days), RSI 60

RSI (14): 59.6 · Price: $17.21

DBD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.8%), weak momentum, RSI 38

RSI (14): 37.7 · Price: $57.04

Fundamentals Snapshot

Metric AMPL DBD
Market Cap — —
Forward P/E 102.6 9.3
Trailing P/E — 28.5
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.7% 0.3%
Operating Margin -0.2% 0.1%
EPS -0.77 2.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DBD is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.